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ABSTRACT 
Breast cancer is one of the most common malignancies among woman. Decades of scientific 
study have linked the overexpression of ERBB2 antigen to aggressive tumors. To target 
aggressive breast cancer, chimeric antigen receptor (CAR) technology can be utilized. For 
this, human T-cells are transduced with a gene sequence encoding a CAR that is specific for 
tumor-associated antigens (TAAs). These genetically-engineered CAR transduced T-cells 
(CAR-T cells) are able to target the tumor antigen without the need for major 
histocompatibility complex (MHC) recognition, rendering it a potentially universal 
immunotherapeutic option. However, efficient transduction of therapeutic gene into human 
T-cells and further cell expansion are challenging. In this study, we reported a successful 
optimization of a transduction protocol using spinoculation on CD3+ T-cells with different 
concentrations of lentiviral plasmid encoding the CAR gene. CD3+T-cells were isolated from 
the peripheral blood mononuclear cells (PBMCs). The constructed CAR gene was inserted 
into a lentiviral plasmid containing the green fluorescent protein (GFP) tag and lentiviral 
particles were produced. These lentiviral particles were used to transduce activated T-cells by 
spinoculation. T-cells were activated using Dynabead-conjugated CD3/CD28 human T-cell 
activator and interleukin-2 (IL-2) before transduction. CD3+ T-cells were selected and GFP 
expression, which indicated transduction, was observed. Future studies will focus on in vitro 
and in vivo models to determine the efficiency of CAR-T cells in specifically targeting 
ERBB2-expressing cells. 
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